The effect of aspirin on platelets and blood vessels in healthy persons and patients with the disease type 2 diabetes.

Phase 1

• Conditions: Type 2 diabetes and Healthy volunteers; MedDRA version: 18.1Level: LLTClassification code 10012594Term: DiabetesSystem Organ Class: 100000004861; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2016-000515-32-DK
• Lead Sponsor: Per Løgstrup Poulsen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-02-29
• Last Update Posted: 13 March 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Diabetics: Age > 18 years and a diagnosis of type 2 diabetes.
Controls: age > 18 years and exclusion of type 2 diabetes by oral glucose tolerance test.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 21
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 21

Exclusion Criteria

Current treatment with antiplatelet drugs or anticoagulants including aspirin.
Treatment with non-steroidal antiinflammatory drugs.
Aspirin hypersensitivity.
Pregnancy.
Gastrointestinal bleeding within the last month.
Platelet disease and/or bleeding diseases.
Low platelet count (< 120 x 109/L).
Active cancer diagnose, chronic or acute infection, dialysis.
Known Cardiovascular disease.
Inability to give informed consent.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified